




FCFRP
FACULDADE DE CIÊNCIAS FARMACÉUTICAS
DE RIBEIRÃO PRETO - USP



university of
 groningen

NanoTop
CENTRO DE NANOTECNOLOGIA MANUFATURADA SISTEMAS E TOXICOLOGIA ADMINISTRATIVA



Self-assembling nanoparticles enhance brain delivery and anti-amyloid activity of NUsc1


Carraro, M. F.^{1,2}; Sebollela, A. A.³; Santos, H. A.² and Lopez, R. F. V.¹

¹ *School of Pharmaceuticals Sciences of Ribeirao Preto, University of Sao Paulo, Sao Paulo, Brazil.*

² *University Medical Center Groningen, University of Groningen, Groningen, the Netherlands.*

³ *Ribeirao Preto Medical School, University of Sao Paulo, Sao Paulo, Brazil.*





Molecular Basis of Alzheimer's Disease



Dementia affects around **55 million** people globally, with projections to reach **132 million** by 2050

World Health Organization, 2023

Alzheimer's disease is the **leading cause of dementia** worldwide (accounting for 60%-80% of cases)


SCHELTENS et al., 2021


Mechanisms of neurotoxicity associated with A β Oligomers:

- **Synapse deterioration**
- **Inhibition of axonal transport**
- **Oxidative stress**
- **Neuron death**
- **Plasticity dysfunction**

Zhao et al, 2006; Wu et al, 2010; Pigino et al, 2009

Decker et al, 2010; Lambert et al, 1998; De Felice et al, 2007; Ryan et al, 2009






How can the neurotoxic effects of A β Os be blocked?


NUsc1 was selected against A β Os by phage display (Velasco et al., 2012);

NUsc1 shows high selectivity and specificity for A β Os (Sebollela et al., 2017);

AAV-NUsc1 treatment prevented and reversed A β O-induced memory impairment in APP/PS1 transgenic mice (Selles et al., 2022).

Learn more
about NUsc1






How can NUsc1 be efficiently delivered to the brain?


Challenge: limited antibody transport across the Blood–Brain Barrier

Strategy: Nose-to-brain delivery

Advantages:

- Direct delivery to the brain, bypassing the BBB;
- Avoidance of first-pass metabolism ;
- Non-invasive and painless administration.






Nose-to-Brain Delivery System for NUsc1 :

Polymeric nanoparticles (NPs) loaded with NUsc1:

HA is a biopolymer and a major component of the brain extracellular matrix. Its mucoadhesive properties may enhance nasal residence time.




Review > Front Mol Neurosci. 2021 Oct 28;14:759729. doi: 10.3389/fnmol.2021.759729. eCollection 2021.

Arginine and Arginine-Rich Peptides as Modulators of Protein Aggregation and Cytotoxicity Associated With Alzheimer's Disease

Somayra S A Mamsa^{1,2}, Bruno P Meloni^{2,3,4}


Affiliations + expand


PMID: 34776866 PMCID: PMC8581540 DOI: 10.3389/fnmol.2021.759729



(Ng and Konermann, 2024)



(Lee and Spicer, 2000)






Physicochemical Characterization of NUsc1-NPs:

Dynamic Light Scattering (DLS):




Nanoparticle Tracking Analysis:

	Mean (nm)	Span	Concentration (particles/ml) :
Blank NP	156.2 ± 1.4	0.5	$(1.72 \pm 0.02) \times 10^{11}$
NUsc1-NP	192.9 ± 3.6	0.96	$(3.68 \pm 0.23) \times 10^{10}$




Transmission Electron Microscopy (TEM):





NUsc1 Encapsulation Efficiency (%EE):


NUsc1-NPs	Free NUsc1 (µg/mL)	Encapsulated NUsc1 (µg/mL)	%EE
Average ± SD	6.9 ± 0.5	13.07 ± 0.5	65.3 ± 2.5




Evaluation of NUsc1-NPs Cytotoxicity:

- Resazurin-Based Viability Assay in Human Neuroblastoma and Human Nasal Epithelial Cells
- 24-hour treatment







Monitoring of the A β aggregation pathway by thioflavin T:



Transmission Electron Microscopy (TEM):




A 10 μ M solution of A β peptide was incubated at 37 $^{\circ}$ C for 36 h in the presence of free NUsc1 (10 μ g/mL), blank NPs, or NUsc1-NPs (33% v/v per well) (n = 4). Amyloid fibril formation was monitored by the increase in Thioflavin T (ThT) fluorescence intensity.



Intranasal administration of NUsc1-NPs:

Preliminary *in vivo* study of brain delivery of NUsc1-NPs (WT mice):

Intranasal administration
Total vol.: 20 μ L (10 μ L per nostril)
NUsc1 dose: 20 μ g




CEUA- FCFRP (nº 25.1.54.60.3)


Groups:

Naïve
NUsc1-NPs (1 h, 4 h and 24 h)
Blank NPs (4 h)
free NUsc1 (4 h)


Euthanasia/
Perfusion



Brain Extraction




Slicing




Immunofluorescence


ADD **PRIMARY** ANTIBODY
4°C 24h


ADD **SECONDARY**
ANTIBODY and **DAPI**
rT 2h






Intranasal Delivery of NUsc1 to the Hippocampus





Intranasal Delivery of NUsc1 to the Hippocampus



Acknowledgments

Prof. Dr. Renata Lopez (Supervisor - FCFRP/USP)
Prof. Dr. Hélder Santos (Supervisor - UMCG/UG)
Prof. Dr. Adriano Sebollela (Collaborator – FMRP/USP)
Prof. Dr. Luciane Alberici (Collaborator – FMRP/USP)
Eduarda Rios (FCFRP/USP)
Dr. Jonathas Santos (FCFRP/USP)
Silvana Chrodrau (FMRP/USP)



Funding Agencies :



Nanotop



Santos' Lab



SebolleLab



Thank you for your attention.

mariane.carraro@usp.br